

# Proapoptotic Bid mediates the Atr-directed DNA damage response to replicative stress

Y Liu<sup>1</sup>, CC Bertram<sup>1</sup>, Q Shi<sup>2</sup> and SS Zinkel<sup>\*,1,2</sup>

Proapoptotic BH3 interacting domain death agonist (Bid), a BH3-only Bcl-2 family member, is situated at the interface between the DNA damage response and apoptosis, with roles in death receptor-induced apoptosis as well as cell cycle checkpoints following DNA damage.<sup>1–3</sup> In this study, we demonstrate that Bid functions at the level of the sensor complex in the Atm and Rad3-related (Atr)-directed DNA damage response. Bid is found with replication protein A (RPA) in nuclear foci and associates with the Atr/Atr-interacting protein (Atrip)/RPA complex following replicative stress. Furthermore, Bid-deficient cells show an impaired response to replicative stress manifest by reduced accumulation of Atr and Atrip on chromatin and at DNA damage foci, reduced recovery of DNA synthesis following replicative stress, and decreased checkpoint kinase 1 activation and RPA phosphorylation. These results establish a direct role for the BH3-only Bcl-2 family member, Bid, acting at the level of the damage sensor complex to amplify the Atr-directed cellular response to replicative DNA damage.

*Cell Death and Differentiation* (2011) 18, 841–852; doi:10.1038/cdd.2010.151; published online 26 November 2010

The Bcl-2 family of proteins regulates the intrinsic pathway of programmed cell death or apoptosis. The BH3-only members of the family function as sensors, relaying death signals to the core apoptotic machinery at the mitochondria. BH3-only BH3-interacting domain death agonist (Bid) has a unique function in apoptosis to interconnect the death receptors of the extrinsic pathway to the mitochondrial amplification loop of the intrinsic pathway.<sup>4,5</sup> Despite the potent role of Bid in apoptosis, Bid-deficient mice develop normally, but show deregulated myeloid homeostasis, culminating in a clonal disorder closely resembling human chronic myelomonocytic leukemia (CMML).<sup>6</sup> Bid-deficient myeloid progenitor cells (MPCs) show an increased mitomycin c-induced chromosomal breaks,<sup>2</sup> and Bid-deficient leukemias show chromosomal abnormalities.<sup>6</sup> Following DNA damage, Atm, and/or Atm and Rad3-related (Atr) phosphorylate Bid on Ser61/64 and Ser78, and this phosphorylation is required for proper regulation of S phase after DNA damage.<sup>1,2,7</sup> Thus, Bid has two distinct and separable functions in apoptosis and the DNA damage response.

A highly regulated response program senses and repairs DNA damage.<sup>8</sup> Two phosphoinositide 3-kinase-related protein kinases (PIKKs), Atm, and Atr, sense DNA damage at the site of the DNA lesion and activate downstream transducers to engage the checkpoint and DNA repair machinery,<sup>8</sup> or the apoptotic pathway.<sup>10</sup> Atm responds primarily to double strand breaks, and Atr to replication protein A (RPA)-coated single-stranded DNA (ssDNA) by interaction with its stable binding partner Atr/Atr-interacting protein (Atrip).<sup>9–11</sup>

Stalled replication forks created by replicative stress produce a distinct DNA lesion comprised of RPA-coated ssDNA adjacent to a stretch of dsDNA. RPA recruits a multiprotein complex at the site of the DNA lesion, comprised of Atrip, interacting with RPA via its checkpoint recruitment domain (CRD) and its stable binding partner Atr.<sup>12</sup> Rad17 independently recruits the Rad9–Hus1–Rad1 complex (9–1–1 complex) to stalled replication forks.<sup>13,14</sup> The 9–1–1 complex then recruits topoisomerase-binding protein 1 (TopBP1),<sup>15</sup> to associate with Atrip and Atr, and stimulate Atr kinase activity.<sup>16</sup> Activated Atr phosphorylates a multitude of downstream effectors to initiate the complex cellular response to replicative stress, including activation of checkpoints, DNA repair, and apoptosis.

Proapoptotic Bid functions in apoptosis as well as the DNA damage response.<sup>1–3</sup> Two independent groups have demonstrated that Bid is found in the nucleus after DNA damage, is phosphorylated by Atm and/or Atr, and mediates efficient activation of an S-phase checkpoint.<sup>1,2,17</sup> Bid has also been identified in a screen of proteins phosphorylated in response to DNA damage on consensus Atm/Atr phosphorylation sites.<sup>7</sup> Furthermore, mice expressing mutated Nijmegen breakage syndrome 1 demonstrate defective Atm activation and Bid phosphorylation.<sup>18</sup> Nonetheless, the mechanism by which Bid interacts within the DNA damage response is unknown, and there is some controversy in the literature, primarily concerning the generality of role of Bid in DNA damage-induced apoptosis.<sup>19</sup> Of note, transient knockdown (KD) of Bid was not tested in the above studies, therefore, the

<sup>1</sup>Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, USA and <sup>2</sup>Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA

\*Corresponding author: SS Zinkel, Department of Medicine, Vanderbilt University School of Medicine, 548 PRB, Nashville, TN 37232, USA. Tel: + 615 936 1801; Fax: + 615 936 3853; E-mail: Sandra.zinkel@vanderbilt.edu

**Keywords:** Bid; DNA damage; Atr; Atrip

**Abbreviations:** Atm, ataxia telangiectasia mutated; Atr, Atm and Rad3-related; Bid, BH3-interacting domain death agonist; Chk1, checkpoint kinase 1; CMML, chronic myelomonocytic leukemia; ETOP, etoposide; HU, hydroxyurea; IP, immunoprecipitation; KD, knockdown; MPCs, myeloid progenitor cells; PIKKs, phosphoinositide 3-kinase-related protein kinases; RPA, replication protein A; ssDNA, single-stranded DNA; TopBP1, topoisomerase-binding protein 1

Received 09.8.10; revised 13.10.10; accepted 14.10.10; Edited by JM Hardwick; published online 26.11.10

differences may have been attributable to compensation of cells to the absence of Bid in a given experimental setting. Indeed, a recent report<sup>20</sup> showed defects in S phase following replicative stress induced by thymidine in *Bid* KD HCT116 cells.

In this study, we demonstrate that Bid facilitates Atr signaling, acting at the DNA damage sensor complex in response to replicative stress. In the absence of Bid, Atr function is limited, as measured by recruitment of Atr and Atrip to chromatin and nuclear foci following hydroxyurea (HU), phosphorylation of Atr substrates, and recovery of DNA replication following replicative stress (stalled replication forks). In addition, Bid is found in nuclear foci with RPA following HU-induced replicative stress, and associates with members of the DNA damage sensor complex, Atr, Atrip, and RPA. Importantly, the Atr/Atrip association with RPA is diminished in the absence of Bid. Furthermore, Bid's Atrip association is required for checkpoint kinase 1 (Chk1) phosphorylation and accumulation of Atrip at nuclear foci following HU. Thus, we demonstrate that Bid facilitates the response of the Atr-mediated pathway to replicative stress through association with Atrip at DNA damage foci, functioning at the level of the sensor complex.

## Results

**Bid is expressed in tissues with proliferating cells.** Our previous results show increased chromosomal damage and increased sensitivity of *Bid*-deficient MPCs after treatment with agents inducing replicative stress.<sup>2,6,17</sup> Bid is highly expressed in tissues that contain proliferating cells, such as thymus, bone marrow, and spleen, as well as intestinal epithelium after DNA damage,<sup>21</sup> but not in tissues comprised primarily of post-mitotic cells, such as brain and lungs (Figure 1a). In addition, the expression level of Bid correlates with that of PCNA, a marker for cell proliferation (Figure 1a). Bid is, therefore, expressed in settings, in which cells are undergoing proliferation.

***Bid*<sup>-/-</sup> bone marrow cells are more sensitive to replicative stress.** We asked whether Bid might have a role *in vivo* to monitor the response to replicative stress by treating mice with HU, a ribonucleotide reductase inhibitor that predominantly triggers activation of the Atr-mediated signaling pathway. Hematopoietic progenitor cells proliferate and repopulate the bone marrow following insult, and are vulnerable to agents inducing replicative stress. *Bid*<sup>-/-</sup> but not *Bid*<sup>+/+</sup> bone marrow cells are more sensitive to systemic treatment with 100 mg/kg HU *in vivo* (Figure 1b), but not to a low dose of infrared radiation (2 Gy), suggesting specific sensitivity to replicative stress. We, thus, demonstrate that *Bid* has a role *in vivo* to mediate the response of bone marrow to HU-induced replicative stress.

**Bid has a role in recovery and completion of DNA replication following HU.** One function of activated Atr that is distinct to Atr among the PIKKs is to facilitate cell cycle re-entry after the release of replicative stress.<sup>22</sup> U2OS cells transfected with siRNA directed against Bid (*Bid* KD) or a


control siRNA (control KD) were arrested in early S phase by 10 mM HU for 24 h. HU was washed out and cells were released into fresh medium with nocodazole to prevent cell division. Asynchronous *Bid* KD and control KD U2OS cells showed similar cell cycle profiles at baseline (Figures 1c and d). *Bid* KD but not control KD U2OS cells demonstrated impaired DNA replication recovery and impaired progression through S phase (Figure 1c, Supplementary Figure S1A), but no significant increase in apoptotic cells as measured by <2N DNA content (Supplementary Figure S1B). Thus, the recovery of DNA replication and completion of S phase after replicative stress was significantly impaired in the absence of Bid further suggesting a defect in Atr activation in the absence of Bid.

**Bid does not mediate TopBP1-directed Atr activation *in vitro*.** To determine whether Bid modulates TopBP1 activation of Atr, Atr–Atrip was purified by immunoprecipitation (IP) from 293T cells, and incubated with purified TopBP1 AAD,  $\gamma$ -<sup>32</sup>P-ATP, and Mcm2 as an Atr substrate,<sup>12</sup> with and without Bid (Supplementary Figure S2A). Atr–Atrip phosphorylated Bid and Mcm2, however, the presence of Bid did not alter Mcm2 phosphorylation. Bid is, thus, a substrate of Atr but does not modulate TopBP1-directed Atr activation in this *in vitro* system.

**Bid has a role in recruitment or maintenance of Atrip to nuclear foci following replicative stress.** In the presence of replicative stress, Atrip and Atr are recruited to stalled replication forks and accumulate in nuclear foci. *Bid*-deficient cells demonstrated decreased Atr/Atrip accumulation in chromatin following HU relative to *Bid*<sup>+/+</sup> cells (Figure 1e). *Bid* KD U2OS cells demonstrate decreased accumulation of Atrip in HU-induced DNA damage foci (Figures 1f and g). Importantly, reintroducing wild-type Bid into *Bid* KD U2OS cells restored Atrip accumulation at nuclear foci (Figures 1f and g). No HU-induced increase in Atr or Atrip levels was seen in control U2OS cells; a modest HU-induced increase in Atr protein level was observed following DNA damage in *Bid*<sup>+/+</sup> but not *Bid*<sup>-/-</sup> MPCs (Supplementary Figure S2B and C). The above data are consistent with a role for Bid in recruitment or maintenance of Atr and Atrip at nuclear foci following DNA damage.

Apoptosis activates DNAases. To rule out Bid-induced apoptosis as the etiology of Atrip accumulation at nuclear foci, we evaluated caspase 3 activation by immunofluorescence following reintroduction of Bid (Supplementary Figure S2D and E). Death receptor stimulation but not HU treatment activates caspase 3 in U2OS cells. Reintroduction of *Bid*<sup>+/+</sup> to *Bid* KD U2OS cells treated with HU does not activate caspase 3, indicating that the Atrip accumulation at nuclear foci is not due to Bid-induced apoptosis.

**DNA damage-induced phosphorylation of Atr substrates is diminished in the absence of Bid.** We next evaluated phosphorylation of the Atr effectors, Chk1 and RPA32. Following HU treatment, Chk1 immunoblot displayed phosphatase-sensitive slower migrating bands that reacted with antibodies specific for phospho-Chk1 (S317) and (S345;




**Figure 1** The cellular recovery from replicative stress and the HU-induced accumulation of Atrip at nuclear foci are impaired in the absence of Bid. **(a)** Bid is highly expressed in hematopoietic tissues. Tissues were harvested from wild-type C57Bl6 mice. Total cell lysates from the indicated tissues were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. The molecular weight markers used in immunoblots are labeled on the right of the blots. **(b)** *Bid*<sup>-/-</sup> bone marrow cells are more sensitive to replicative stress. *Bid*<sup>+/+</sup> and *Bid*<sup>-/-</sup> mice were injected with 100 mg/kg hydroxyurea (HU) for 3 consecutive days. Mice were killed and bone marrow was harvested from mouse femurs and tibia at 24 h after the third injection. *Bid*<sup>+/+</sup> and *Bid*<sup>-/-</sup> mice were irradiated with 2 Gy using a <sup>137</sup>Cs source. Mice were killed and bone marrow was harvested from mouse femurs and tibia 24 h after irradiation. Following lysis of red blood cells, viable bone marrow cells were identified by trypan blue exclusion and counted. *N* = 15 mice for HU treatment and *n* = 10 mice for irradiation treatment. Error bar = 90% confidence interval. *P*-value is calculated by student's *t*-test. **(c)** U2OS cells were transfected with control siRNA or Bid siRNA. After 2 days, cells were exposed to 10 mM HU for 24 h, and released into fresh media containing 1 μg/ml nocodazole for the indicated times. Cells were fixed and stained with 7-AAD and analyzed by flow cytometry. **(d)** U2OS cells were transfected with control siRNA or Bid siRNA for 72 h. Cells were lysed and Bid was detected in immunoblots. **(e)** *Bid*<sup>+/+</sup> and *Bid*<sup>-/-</sup> MPCs were treated with 10 mM HU for 2 h. The chromatin fraction was isolated and extracts were resolved on SDS-PAGE and immunoblotted with the indicated antibodies. **(f)** U2OS cells were transfected with control siRNA or Bid siRNA and wild-type mouse Bid was introduced into the cells simultaneously with siRNA. Cells were treated with 10 mM HU for 5 h, fixed, and stained with anti-Atrip antibody. Representative images of Atrip staining were shown. **(g)** Quantitative analysis of Atrip accumulation at nuclear foci following replicative stress. The percentage of cells with >5 clearly visible Atrip nuclear foci was calculated for each cell type. More than 600 cells were counted in three independent experiments

Figures 2a and b, Supplementary Figure S3A). These bands were diminished in *Bid*<sup>-/-</sup> MPCs following HU treatment (Figures 2a and b). To acutely decrease Bid protein levels, siRNAs targeted against human Bid and mouse Bid mRNA were introduced into human U2OS cells and mouse MPCs, respectively, decreasing Bid levels to <20% of endogenous levels in U2OS cells using siRNA7, and nearly completely using siRNA8 (Figure 2c). *Bid*-deficient U2OS cells (Figure 2c) and MPCs (Figures 2a and b, Supplementary Figure S3B and D) displayed diminished phosphorylated Chk1 following HU or etoposide (ETOP) treatment.

Furthermore, the degree of decreased Chk1 phosphorylation correlated with the degree of *Bid* KD. Interestingly, the Chk1 level is increased in *Bid*<sup>-/-</sup> MPCs (Figures 2a and b), but not in U2OS cells when Bid was knocked down by siRNA (Figure 2c), consistent with a compensatory increase in Chk1 levels in the setting of chronic absence of Bid, but not when Bid is lost acutely. These results implicate Bid in mediating Atr function.

We next evaluated effectors of the DNA damage response, such as Cdc25a in *Bid*<sup>+/+</sup> and *Bid*<sup>-/-</sup> cells. Cdc25a is phosphorylated by Chk1 following replicative stress, targeting



**Figure 2** The phosphorylation of Atr substrates are diminished in Bid-deficient cells following replicative stress. (a) Phosphorylated mouse Chk1 presents as a shifted band. Bid +/+ and Bid -/- MPCs were treated with 10 mM HU for 2 h. Whole-cell extracts were incubated with 10 U Calf Intestinal Alkaline Phosphatase (Invitrogen)/100  $\mu$ g lysate, resolved by SDS-PAGE and immunoblotted with anti-Chk1, anti-pChk1 (S317), or anti-pChk1 (S345) as indicated. Solid arrows denote the mobility of shifted phosphorylated Chk1, and dashed arrows denote the mobility of unphosphorylated Chk1. (b) Bid +/+ and Bid -/- MPCs were treated with 10 mM HU for the indicated times. Total cell lysate was resolved by SDS-PAGE followed by immunoblotting with the indicated antibodies. (c) U2OS cells were treated with Bid-specific siRNA no.7, Bid-specific siRNA no.8, or control siRNA for 72 h. Bid KD and control KD cells were treated with 10 mM HU or 25  $\mu$ M ETOP for 2 h, and total cell lysate was resolved by SDS-PAGE followed by immunoblotting with the indicated antibodies. (d) U2OS cells transfected with control siRNA or Bid siRNA (no. 8) for 72 h were treated with 10 mM HU for 2 h. Whole-cell lysates were immunoprecipitated with anti-Chk1 antibody, and the immunoprecipitated product was incubated with 1  $\mu$ g GST-Cdc25C protein, 10  $\mu$ M cold ATP and 5  $\mu$ Ci  $\gamma$ -<sup>32</sup>P-ATP in kinase buffer. Chk1 kinase reactions were resolved on SDS-PAGE, stained with SimplyBlue SafeStain (Invitrogen) to visualize GST-cdc25c levels, and analyzed by autoradiography. (e) Bid +/+ and Bid -/- MPCs were treated with 10 mM HU over time. Total cell lysate was resolved by SDS-PAGE followed by immunoblot with the indicated antibodies. Relative band intensity has been measured by densitometry analysis. (f) U2OS cells were transfected with control siRNA or Bid siRNA for 72 h, and then treated with 10 mM HU over time. Total cell lysate was resolved by SDS-PAGE followed by immunoblot with the indicated antibodies. Solid arrow denotes the mobility of shifted phosphorylated RPA32, and dashed arrow denotes the mobility of unphosphorylated RPA32. Relative band intensity was measured by densitometry analysis.


it for degradation.<sup>23,24</sup> Cdc25a degradation following DNA damage was delayed in Bid -/- MPCs as well as in Bid KD U2OS cells (Figures 2b and c, Supplementary Figure S3B). Interestingly, Cdc25a levels are increased in untreated Bid -/- MPCs but not in Bid KD U2OS cells, consistent with a compensatory increase in Cdc25a levels in the setting of prolonged loss of Bid. These results implicate Bid in mediating Chk1 function.

We further evaluated Chk1 kinase activity via IP of Chk1 from control siRNA and Bid siRNA-transfected U2OS cells followed by incubation with GST-cdc25C and  $\gamma$ -<sup>32</sup>P-ATP. The anti-Chk1 antibody immunoprecipitated both Chk1 and phosphorylated Chk1 (Supplementary Figure S3E and F). Following HU treatment, Bid KD U2OS cells demonstrated decreased kinase activity relative to control KD cells suggesting that the HU-induced Chk1 activity, or a kinase associated with Chk1, is decreased in the absence of Bid

(Figure 2d). These results strongly suggest that HU-induced Chk1 activation is decreased in the absence of Bid.

We next evaluated phosphorylation of the Atr targets p53 and RPA32 following replicative stress. p53 phosphorylation at Ser15 (Figure 2e, Supplementary Figure S4A), and the HU-induced expression levels of the p53 target genes *p21* and *Noxa*<sup>25</sup> were diminished (Supplementary Figure S4B) in Bid -/- MPCs following HU treatment. Furthermore, RPA32 phosphorylation was decreased in Bid -/- MPCs (Figure 2e) and in U2OS cells upon siRNA KD of Bid (Figure 2f). Thus, in the absence of Bid, phosphorylation of multiple Atr substrates was diminished, consistent with a role for Bid in Atr activation.

In contrast, the autophosphorylation of Atm was normal in the absence of Bid following ETOP treatment in U2OS cells (Supplementary Figure S4C), suggesting that Bid does not have a major role in Atm activation. In addition, Chk1 phosphorylation was diminished in Bid/Atm-deficient U2OS



**Figure 3** Bid associates and co-localizes with Atr/Atrip/RPA complex following replicative stress. (a) *Bid*<sup>+/+</sup> and *Bid*<sup>-/-</sup> MPCs were treated with 10 mM HU for 2 h. Bid was immunoprecipitated from nuclear extracts using biotin-conjugated anti-Bid antibody and streptavidin-agarose beads. Samples were analyzed using SDS-PAGE followed by immunoblotting with the indicated antibodies. The asterisk (\*) indicates a crossreacting band. Transcription factor RUNX1 was used as a negative control. (b) U2OS cells were treated with 10 mM HU for 2 h. Cells were harvested, and Atrip was immunoprecipitated from nuclear extracts using anti-Atrip (401) antibody. Immunoprecipitates were analyzed using SDS-PAGE followed by immunoblotting with anti-Bid and anti-Atrip antibodies. (c) U2OS cells were treated with 10 mM HU for 2 h. Cells were harvested, and RPA was immunoprecipitated from nuclear extracts using anti-RPA70 antibody. Immunoprecipitates were resolved by SDS-PAGE followed by immunoblotting with anti-Bid and anti-RPA70 antibodies. (d) The interaction between Bid and Atr complex is independent of DNA. *Bid*<sup>+/+</sup> MPCs were treated with 10 mM HU for 2 h. Then, the nuclear fraction was purified and incubated with 250U Benzonase Nuclease (Novagen). Then, Bid was immunoprecipitated from nuclear extracts using biotin-conjugated anti-Bid antibody and streptavidin-agarose beads. Samples were analyzed using SDS-PAGE followed by immunoblotting with the indicated antibodies. (e) *Bid*<sup>-/-</sup> MEFs harboring HA-tagged Bid were synchronized in low serum medium (0.1% FBS-DMEM) for 24 h. Following synchronization, cells were released into complete medium (10% FBS-DMEM). At 17 h after release, cells were left untreated (18 h serum) or treated for 1 h with 1 mM HU (18 h serum plus HU). Then, cells were fixed and stained for anti-HA and anti-RPA32 antibodies. Representative images in (f) were captured by a Zeiss LSM 510 inverted confocal microscopy. Scale bars represent 10  $\mu$ m

cells as well as *Bid*-deficient U2OS cells (Supplementary Figure S4D), suggesting that the function of Bid in the Atr-mediated response is independent of Atm.

Chk1 phosphorylation increases in S phase. We observed no significant difference in the percentage of cells in S phase between *Bid*<sup>+/+</sup> and *Bid*<sup>-/-</sup> cells (Supplementary Figure S5A and B). To stringently evaluate the status of Chk1 phosphorylation at a defined stage of the cell cycle, we performed intra-cellular phospho-Chk1 staining with 7-AAD costaining followed by flow cytometry. *Bid*<sup>-/-</sup> cells showed decreased numbers of phospho-Chk1<sup>+</sup> cells, and the mean fluorescence index of phospho-Chk1 staining was significantly decreased relative to *Bid*<sup>+/+</sup> cells within the total cell population and in cells in late S/G2/M (Supplementary Figure S5D and K), demonstrating on a per cell basis that phospho-Chk1 is decreased in *Bid*<sup>-/-</sup> cells. Thus, the differences in Chk1 phosphorylation observed in *Bid*-deficient cells were not because of an alteration of the cell cycle profile.<sup>26–28</sup>

**Bid associates with Atr/Atrip/RPA.** The findings outlined above implicate a role for Bid very early in the DNA damage response, at the level of Atr activation and recruitment to DNA damage foci. We, therefore, examined the ability of Bid to associate with the DNA damage sensor complex, composed of Atr, Atrip, and RPA.<sup>9</sup> Atr, Atrip, and RPA co-immunoprecipitated with Bid from nuclear extracts, and this co-IP was enhanced after HU treatment (Figure 3a). Mouse but not human Bid co-migrates with the immunoglobulin light chain on SDS-PAGE, therefore, we performed the reverse IP in U2OS cells. When endogenous Atrip or RPA was immunoprecipitated from the nuclear fraction of U2OS cells, Bid was detected in the immunoprecipitated product (Figures 3b and c). Furthermore, when purified Bid was incubated with purified RPA complex, RPA complex immunoprecipitated with Bid (Supplementary Figure S6A). The anti-Bid antibody did not nonspecifically precipitate DNA as shown by immunoblotting with anti-Runx1 antibody. The above results are

consistent with an association of Bid with the RPA complex at stalled replication forks following replicative stress.

**The Bid/Atr/Atrip/RPA association does not require DNA.** To determine whether the association of Bid with the RPA/Atr/Atrip complex requires DNA, we isolated nuclear extracts from HU-treated *Bid*<sup>+/+</sup> and *Bid*<sup>-/-</sup> MPCs and incubated the extracts with DNAase. There is no change in the association of Bid with Atr or RPA70 following DNAase treatment (Figure 3d), indicating that the association of Bid with RPA/Atr/Atrip is not dependent on intact DNA.

**Bid is found at nuclear foci with RPA following HU.** The above results implicate a role for Bid at the site of DNA damage following replicative stress, at stalled replication forks. To determine whether Bid is present at these structures following DNA damage, we synchronized *Bid*<sup>-/-</sup> MEFs stably expressing FlagHA-tagged Bid (FHABid MEFs) in G1 by incubation in reduced serum (0.1% FBS) medium for 24 h, then released the cells into complete medium (10% FBS; Figure 3e). The population of S-phase cells was enriched 17 h after release (Figure 3e), whereupon cells were left untreated or treated with 1 mM HU for 1 h. Immunofluorescence using antibodies to HA and RPA32 revealed the presence of Bid and RPA32 in nuclear foci in synchronized FHABid cells treated with HU, but not in untreated cells, or serum-starved cells (Figure 3f, Supplementary Figure S6B). Bid is thus present in the region of stalled replication forks following HU treatment.


**Bid helix 4 associates with Atrip.** To determine the domain of Bid that associates with Atrip, various Bid mutants were transiently overexpressed in 293T cells with HA-tagged Atrip (Figure 4a). Cells that were untreated or treated with HU were harvested, and Bid was immunoprecipitated from total cell extracts. Interestingly, Bid mutants targeting the well-studied BH3 domain and phosphorylation sites still associated with Atrip (Figure 4b). Successive deletion of  $\alpha$ -helices beginning at the C terminus of Bid revealed that the Bid–Atrip association was maintained and enhanced following DNA damage even in the absence of helices 5–8, but not helix 4 (data not shown). On the basis of nuclear magnetic resonance structure of Bid (Figure 4c), Leu105, Leu109, Gln112, and Asn115 in helix 4 are on the outer face of the protein, providing a candidate surface to interact with other proteins.<sup>29,30</sup> Site-directed mutagenesis of Leu105 and Leu109 to polar cysteine residues (BidH4A), or mutation of Gln112 and Asn115 to alanine residues (BidH4B), severely diminished the Bid–Atrip association (Figures 4a and d). Mutating residues in the loop between helices 4 and 5 by mutating Ser117 and Ser119 to alanines (loop A) or mutating Glu120, Glu121, and Asp122 to glycines (loop B) had a less severe effect (Figures 4a and d). Finally, we purified *Escherichia coli*-expressed Bid and His–MBP–fused Atrip. Bid, but not BidH4A or BidH4B immunoprecipitated with full-length Atrip (Figure 4e). The above data indicate that Bid interacts with Atrip, and this interaction is dependent on an intact Bid helix 4. Of note, Bid helix 4 is highly conserved between human, mouse, and rat (Figure 4c), underscoring its potential importance, and

raising the possibility that the function of Bid in the DNA damage signaling pathway might be a unique characteristic of Bid among Bcl-2 family members.

**Bid binds to the Atrip coiled-coil domain.** To determine the domain of Atrip required for the association with Bid, various HA-tagged Atrip mutants,<sup>31</sup> were tested for Bid–Atrip association in 293T cells as above (Figures 4f and i). Deletion of the first 107 amino acids of Atrip, including the CRD or amino acids 181–435 (TopBP1-binding domain) had no effect on the association of Bid with Atrip (Figure 4g). Deletion of amino acids 112–414 significantly decreased the Bid–Atrip association (Figures 4g and h). Although the deletion of Atrip amino acids 112–225 resulted in decreased stability of the protein,<sup>31</sup> the association of Atrip $\Delta$ 112–225 with Bid is decreased. As the Bid–Atrip association was preserved in deletions involving the TopBP1 domain, but not in deletions involving amino acids 112–225, the above data are most consistent with an association of Bid with the Atrip coiled-coil domain. Cells harboring Atrip/ $\Delta$ 112–225 mutant showed defects in Chk1 phosphorylation and Atrip nuclear foci following replicative stress.<sup>31</sup>

**Bid helix 4 mutants maintain cell death activity.** BidH4A and BidH4B maintain a comparable ability to bind to Bcl-2 and Mcl-1, as well as the ability to be cleaved by caspase 8 (Figures 5a and c). We further tested the ability of these helix 4 mutants to induce cell death by stably introducing Bid<sup>+/+</sup> and BidH4A and H4B into U2OS cells. siRNA KD of endogenous Bid but not control KD resulted in protection from TRAIL/cycloheximide-induced cell death. Trail-induced cell death was restored by re-introduction of Bid<sup>+/+</sup> or BidH4A and BidH4B but not Bid mutated in the BH3 domain (Figure 5d). HU treatment induced minimal cell death in U2OS cells. Expression of Bid<sup>+/+</sup> as well as BidH4A and BidH4B increased cell death following HU to a similar extent (Supplementary Figure S6C). Thus, Bid helix 4 mutants are able to be cleaved by caspases and to induce cell death following death receptor stimulation or HU treatment, providing further evidence that the structure and cell death function of Bid helix 4 mutants is intact (Figures 5a and d and data not shown). Furthermore, the two functions of Bid, cell death and DNA damage can be structurally separated, providing additional evidence that the DNA damage and apoptotic functions of Bid are distinct.

**Bid helix 4 mediates the Atr-directed DNA damage response.** To further define the role of Bid helix 4 in the Atr-directed DNA damage response, we reintroduced BidH4A or BidH4B into *Bid* KD U2OS cells, and evaluated HU-induced accumulation of Atrip at nuclear foci, Chk1 phosphorylation, DNA damage, and recovery and completion of DNA replication. Bid helix 4 mutants failed to restore HU-induced accumulation of Atrip at DNA damage foci (Figures 6a and b) or Chk1 phosphorylation in Bid KD U2OS cells (Figure 6c). To assess DNA damage following replicative stress, we performed alkaline Comet assays following HU treatment. *Bid* KD U2OS cells demonstrated increased DNA




**Figure 4** The helix 4 domain of Bid interacts with the coiled-coil domain of Atrip. **(a)** Schematic illustration of mouse Bid structure. **(b)** Cells (293T) were co-transfected with HA-Atrip/pLPCX, and either wild-type Bid, or Bid mutated in the BH3 domain or Bid mutated in the Atr/ATR consensus phosphorylation sites. Bid was immunoprecipitated from whole-cell extracts using anti-Bid antibody. Samples were resolved on SDS-PAGE followed by immunoblotting with the indicated antibodies. **(c)** Sequence alignment of the helix 4 and helix 5 of Bid among different species. Helix 4 and helix 5 are labeled as purple arrows. The GenBank accession numbers of the sequences used here are: *Homo sapiens* (NM\_197966), *Mus musculus* (NM\_007544), *Rattus norvegicus* (NM\_022684), *Gallus gallus* (NM\_204552), *Danio rerio* (NM\_001079826), *Sus scrofa* (NM\_001030535), *Xenopus laevis* (NM\_001095594), *Xenopus tropicalis* (NM\_001097226), and *Bos taurus* (NM\_001075446). The alignment was performed by Clustal X. The Leu105 and Leu109 in helix 4 are labeled as green stars. The Gln112 and Asn115 in helix 5 are labeled as cyan stars. Loop A amino acids are dark blue, Loop B amino acids are pink. The same amino acids are labeled in the nuclear magnetic resonance structure of Bid.<sup>30</sup> Helix 4 is denoted in red, and is on an exposed surface of Bid. The BH3 domain is facing out of the page. **(d)** Cells (293T) were co-transfected with HA-Atrip/pLPCX, and wild-type Bid or Bid harboring mutations in helix 4: mutation of green stars to polar cysteine residues (H4A), or of cyan stars to alanine residues (H4B), or of dark blue stars at the end of helix 4 to alanine residues (loop A), or of pink stars in the loop region between helices 4 and 5 to glycine (loop B) Bid was immunoprecipitated from whole-cell extracts and samples were analyzed as above. **(e)** Wild-type or helix 4-mutated Bid and His-MBP-Atrip protein were purified from *E.coli*. Bid (10 μg) and 100 μg His-MBP-Atrip protein were incubated in binding buffer at room temperature for 30 min. Bid was immunoprecipitated using anti-Bid antibody, and the immunoprecipitated proteins were resolved on SDS-PAGE and immunoblotted with the indicated antibodies. **(f)** Schematic illustration of Atrip structure. CRD, checkpoint recruitment domain. CC, coiled-coil domain. TopBP1, TopBP1-interacting domain. ATR, Atr-binding domain. **(g–i)** Wild-type Bid and HA-tagged full-length or various truncated Atrip constructs were overexpressed in human 293T cells. Then the cells were treated with 10 mM HU for 2 h and Bid was immunoprecipitated by anti-Bid antibody. The immunoprecipitated products were detected by anti-Bid and anti-HA antibodies

damage relative to control KD cells as measured by tail moment. Expression of Bid +/+ but not BidH4A or BidH4B in Bid KD U2OS cells restored DNA damage levels to those observed in control KD cells. (Figure 6d). In addition, Bid +/+ but not BidH4A or BidH4B rescued the recovery and completion of DNA replication in Bid-deficient U2OS cells following HU (Figures 6e and f). Taken together, these results

are consistent with a role for Bid in Atr activation, mediated by an interaction of Bid helix 4 with Atrip.

**The RPA/Atr/Atrip association is decreased in the absence of Bid.** To determine whether Bid alters the association of Atr/Atrip and RPA, we immunoprecipitated RPA70 or Atr from nuclear extracts of HU-treated Bid +/+



**Figure 5** Mutations in helix 4 domain of Bid do not significantly change the function of Bid in the extrinsic cell death pathway. (a) Helix 4 mutated Bid binds with other Bcl-2 family proteins. Cells (293T) were transfected with wild-type Bid or helix 4-mutated Bid. Bid was immunoprecipitated from whole-cell extracts. Immunoprecipitates were resolved by SDS-PAGE followed by immunoblotting with anti-Bid, anti-Bcl-2 and anti-Mcl-1 antibodies. All the samples were run in the same gel with interrupted lanes deleted. (b) Helix 4-mutated Bid show similar sensitivity as wild-type Bid to caspase 8. Purified wild-type and two helix 4 Bid mutants (H4A and H4B) were cleaved by active caspase 8 (Millipore) *in vitro* for 0.5 and 1 h. The full-length and truncated Bid in reaction products were analyzed by anti-Bid antibody in immunoblots. (c) U2OS cells overexpressing HA-tagged wild-type or helix 4-mutated Bid was transfected with Bid siRNA for 72 h. Silent mutations were introduced in the Bid siRNA-target region so that only endogenous Bid was knocked down by Bid siRNA. Then, cells were treated with 50 ng/ml TRAIL and 5  $\mu$ g/ml cycloheximide (CHX) for 4 h. Total cell lysate was analyzed by SDS-PAGE followed by immunoblotting with anti-Bid antibody. Solid and dashed arrows denote endogenous Bid and overexpressed Bid, respectively. (d) Cells harboring helix 4-mutated Bid show similar sensitivity to TRAIL/CHX treatment. U2OS cells overexpressing HA-tagged wild-type or various Bid mutations was transfected with Bid siRNA for 72 h. Then, cells were treated with 50 ng/ml TRAIL and 5  $\mu$ g/ml CHX over time. The apoptotic cells were detected by Annexin V-FITC Apoptosis Detection Kit (BioVision, Mountain View, CA, USA)

and *Bid*<sup>-/-</sup> MPCs. The association of Atr/Atrip and RPA was decreased in the absence of Bid (Figure 7a). In addition, there was a trend toward decreased RPA foci in the absence of Bid (Supplementary Figure S6D and E). Taken together, our data are most consistent with a role for Bid to facilitate Atr signaling through modulating the DNA damage sensor complex.

## Discussion


The BH3-only Bcl-2 family members serve as sensors for cellular damage, transducing death signals to the multidomain family members at the mitochondria. These proapoptotic BH3-only proteins may function by participating in fundamental cellular processes,<sup>2,17,32,33</sup> in position to sense potentially catastrophic perturbations in cell function and signal to the core apoptotic machinery. Bid has been shown to be a substrate of Atm/Atr and loss of *Bid* results in an aberrant S-phase response to DNA damage.<sup>2,17</sup>

In this study, we demonstrate that Bid functions at a remarkably proximal position in the Atr-mediated DNA damage response to replicative stress, associating with Atr, Atrip, and RPA, in the DNA damage sensor complex. In our study, *Bid*-deficient cells exhibit several phenotypes consistent with limited Atr function following replicative stress: (1) *Bid*<sup>-/-</sup> cells are hypersensitive to replicative stress *in vitro*, *ex vivo*<sup>2</sup> and *in vivo* (Figure 1b); (2) cell cycle re-entry ability is limited in *Bid*-deficient cells following HU withdrawal (Figure 1c); (3) chromatin-bound Atr and Atrip are significantly

decreased following treatment with HU (Figure 1e); (4) activation of the Atr substrates Chk1 and RPA is decreased (Figure 2); and (5) the association of Atr/Atrip and RPA is diminished in the absence of Bid (Figure 7a). The data presented above clearly place Bid in the DNA damage response at the level of the sensor complex, and are consistent with a role for Bid in stabilization of the Atr/Atrip DNA damage sensor complex at nuclear foci following replicative stress, potentially by acting as a bridging protein. Alternatively, Bid may have a role in the stabilization of the replication fork after DNA damage.

Cells respond to stalled replication fork progression by activating signal transduction pathways to initiate a complex set of responses, including checkpoint activation, DNA repair, and in settings of irreparable DNA damage, programmed cell death or apoptosis.<sup>8</sup> A multiprotein complex assembles in a highly coordinated and regulated manner at the site of the DNA lesion. RPA senses the accumulation of single-stranded DNA at stalled replication forks, and has a central role in checkpoint activation through interaction with Atrip to recruit Atr to the site of the DNA lesion. A unified model for activation of Atr/Atrip incorporating the current data in the literature on the role of the association with RPA-ssDNA has not yet developed. Atr-Atrip bound to RPA-coated single stranded DNA is not sufficient for checkpoint activation, but requires the ordered recruitment of additional factors, including the 9-1-1 complex and TopBP1 for downstream signaling to effect the complex response to DNA damage.<sup>34,35</sup> This study places Bid, a member of the Bcl-2 family, in association with key






**Figure 6** An intact Bid helix 4 is required for Bid's function following HU treatment. (a) U2OS cells transfected with control siRNA or Bid siRNA, and Bid KD cells with rescue by wt-Bid, H4A, H4B or phospho-mutated (S/A) Bid were treated with 10 mM HU for 5 h, fixed, and stained with anti-Atrip antibody. Representative images of Atrip staining were shown. (b) Quantitative analysis of Atrip accumulation at nuclear foci following replicative stress. The percentage of cells with > 5 clearly visible Atrip nuclear foci was calculated for each cell type. More than 600 cells were counted in three independent experiments. (c) U2OS cells were treated with control siRNA or Bid siRNA for 72 h. Wild-type mouse Bid, Bid H4A, Bid H4B, or vector alone was introduced into the cells simultaneously with siRNA. Cells were treated with 10 mM HU for 2 h. Total cell lysate was resolved on SDS-PAGE and immunoblotted as above. Relative band intensity of pChk1 signal has been measured by densitometry analysis. (d) U2OS cells overexpressing HA-tagged wild-type or helix 4-mutated hBid was transfected with Bid siRNA for 72 h. Silent mutations were introduced in the Bid siRNA-target region so that only endogenous Bid was knocked down by Bid siRNA. Then, cells were treated with HU overnight. The untreated and treated cells were collected in ice-cold PBS and detected in alkaline comet assay. At least 60 randomly chosen comets/sample were analyzed by CometScore Program Version 1.5. \* $P < 0.05$ . (e) U2OS cells overexpressing HA-tagged wild-type or helix 4-mutated hBid was transfected with Bid siRNA for 72 h. Silent mutations were introduced in the Bid siRNA-target region so that only endogenous Bid was knocked down by Bid siRNA. Then, cells were treated with HU for overnight and released into fresh media containing 1  $\mu$ g/ml nocodazole for the indicated times. Cells were fixed and stained with propidium iodide. Live cells were gated on FSC/SSC and analyzed by flow cytometry. The quantitative analysis of the arrested G1/early S phase cells following 32 h HU withdrawal was shown in (f). \* $P < 0.05$ . (f) The quantitative analysis of the arrested G1/early S-phase cells following HU withdrawal in Figure 6e. Data were collected from three independent experiments. \* $P < 0.05$

proteins of the sensor complex. We further demonstrate that Bid has a role in the stable association of Atr/Atrip and RPA, and in an efficient Atr-mediated DNA damage response following replicative stress.

Following genotoxic stress, Atr/Atr phosphorylate Bid at Ser61 and Ser78.<sup>2</sup> In this study, we found that mutation in Ser61/64/78 attenuates the induction of the Bid-Atrip interaction following HU, but does not abrogate the interaction (Figure 4b).



**Figure 7** A proposed model for Bid in the Atr-mediated DNA damage response to replicative stress. **(a)** The damage complex is unstable in *Bid*<sup>-/-</sup> MPCs following HU treatment. *Bid*<sup>+/+</sup> and *Bid*<sup>-/-</sup> MPCs were treated with 10 mM HU for 2 h. Then, the nuclear fraction was purified and RPA or Atr was immunoprecipitated from nuclear extracts. The immunoprecipitated samples were analyzed using SDS-PAGE followed by immunoblotting with the indicated antibodies. **(b)** Schematic model of a proposed role for Bid in the Atr-mediated DNA damage signaling pathway. Bid serves as a mediator in the Atr-directed response to replicative stress at the level of Atr/Atrip activation. Bid associates with the Atr/Atrip complex via Atrip. Thus, Bid functions at the level of the sensor complex, to facilitate and amplify Atr-directed Chk1 activation and ensure rapid and efficient checkpoint activation

In addition, reintroduction of Bid<sup>S61/64/78A</sup> only partially rescues the defects of Atrip nuclear foci in *Bid* KD U2OS cells (Figures 6a and b). Further investigation is required to clarify the detailed mechanism of Bid phosphorylation in the DNA damage response.

Recently, Mcl-1 has been demonstrated to be a novel mediator in the Atr-Chk1 pathway<sup>36,37</sup> Although the Mcl-1 level is not significantly altered in *Bid*-deficient cells (Supplementary Figure S2B and C), the increased IP of Bid<sup>H4A</sup> with no corresponding increase in the amount of co-immunoprecipitated Mcl-1 (Figure 5a), suggests that binding of Mcl-1 to Bid<sup>H4A</sup> (but not Bid<sup>H4B</sup>) might be reduced. Additional experiments will be required to evaluate the potential interaction of Bid and Mcl-1 in the DNA damage response.

Our initial results differ from results reported by Kaufmann *et al.*<sup>19</sup> with respect to the magnitude of sensitivity of *Bid*<sup>-/-</sup> cells to replicative stress.<sup>2,38</sup> Kaufmann *et al.* used different cell types and activation stimuli, thus the experiments are not directly comparable. Cells vary significantly in their apoptotic response to DNA damage, by both cell lineage as well as differentiation state due both to the percentage of cycling cells as well as the 'hardwiring' of the cell. Immature, rapidly cycling hematopoietic cells showing a high propensity to undergo apoptosis. Fibroblasts are substantially more resistant. Moreover, redundancy in the apoptotic pathway, particularly with respect to the role of a given BH3-only protein, results in variability of apoptotic outcome by cell signal and cell type. We expect that the differences observed between our group and Kaufmann *et al.* were because of the cells and experimental parameters used. This is consistent with an effect that is cell type or context specific as we have proposed.

Distinct from cells defective in other classic mediators/ effectors, such as Atrip, Rad17, and Claspin, the Chk1 activation process is in fact initiated, albeit to a lesser extent, in *Bid*<sup>-/-</sup> cells following DNA damage treatment. Moreover, *Bid*<sup>-/-</sup> mice develop normally, whereas mice lacking the essential mediators/ effectors (Atr, Chk1, Rad17) die early in embryonic development. The normal developmental program in the absence of Bid may reflect the presence of redundancy or tissue/developmental stage specificity to the role of Bid in Atr signaling. Bid is present at high levels in hematopoietic cells, *Bid*<sup>-/-</sup> bone marrow is sensitive to *in vivo* HU, and *Bid*<sup>-/-</sup> mice develop CMML,<sup>39</sup> consistent with a role for Bid in hematopoietic homeostasis and leukemogenesis. Although it is interesting to speculate that the location of Bid as a participant in the DNA damage sensor complex places, it in position to have a key role in determining the fate of a cell following DNA damage, further studies will be necessary to dissect the roles of Bid's apoptotic *versus* DNA damage function in this setting.

## Materials and Methods

**Cell lines and drug treatments.** *Hox11*-immortalized *Bid*<sup>+/+</sup> and *Bid*<sup>-/-</sup> MPCs<sup>6,17</sup> were cultured in IMDM medium (Invitrogen, Carlsbad, CA, USA) with 20% FBS, 100 U/ml penicillin-streptomycin, 2 mM glutamine, 0.1 mM  $\beta$ -mercaptoethanol, and 10% conditioned medium from WEHI cells as a source of IL-3. U2OS cells, *Bid*<sup>-/-</sup> MEFs harboring HA-tagged Bid, were cultured in DMEM (Invitrogen) with 10% FBS, 100 U/ml penicillin-streptomycin, 2 mM glutamine, and 0.1 mM  $\beta$ -mercaptoethanol. Early passage cells (10 < *P* < 20) were treated with HU (Sigma, St. Louis, MO, USA) or ETOP (Sigma) as indicated.

**RNAi treatment and overexpression.** The siRNA oligonucleotides targeting human Bid (SI02661911, SI02662415) were purchased from Qiagen Inc. (Valencia, CA, USA). The no. 7 (SI02661911) and no. 8 (SI02662415) hBid siRNA target sequence are 5'-AAAGACAATGTTAAACTTATA-3' and 5'-CAGGGA TGAGTGATCACAAA-3', respectively. For U2OS cells, the transfection of Bid siRNA and control siRNA (1027310, target sequence: 5'-AATTCTCCGAACGTGTC ACGT-3') was mediated by Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Without specific mention, no.7 and no.8 hBid siRNA was mixed together and used as Bid siRNA in experiments. After 72 h transfection, the transfected U2OS cells were treated as indicated in the figure legends. For overexpression, siRNA and various Bid constructs in pcDNA3 vector were co-transfected into U2OS cells by Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. After 72 h transfection, the cells were treated with 10 mM HU for 2 h.

**Immunofluorescence staining.** For Atrip nuclear foci, Bid siRNA, or control siRNA was delivered into U2OS cells by Lipofectamine 2000. After 40 h, pcDNA3 vector containing wild-type mouse Bid or H4A mutant Bid or vector alone was introduced by FuGene 6 (Roche, Nutley, NJ, USA). After another 40 h, the cells were treated with 10 mM HU for 5 h. Then, the cells were fixed by 3% paraformaldehyde/2% sucrose solution and permeabilized by Triton X-100 solution (0.5% Triton X-100, 20 mM HEPES pH7.4, 50 mM NaCl, 3 mM MgCl<sub>2</sub>, 300 mM sucrose). Atrip localization was detected by immunofluorescence using anti-Atrip polyclonal antibody 403.<sup>9</sup> The cells were examined using a Leica DM IRBE inverted wide-field microscope (Bannockburn, IL, USA).

For Bid-RPA co-localization analysis, synchronized *Bid*<sup>-/-</sup> MEFs harboring HA-tagged Bid were fixed in cold 3:1 methanol:acetone and blocked for 1 h with 5% Normal Goat Serum (Sigma) in PBS. RPA was detected by immunofluorescence using Rat anti-RPA32 antibody (Cell Signaling, Danvers, MA, USA) and Alexa Fluor 546 conjugated Goat anti-Rat IgG antibody (Invitrogen). HA-tagged Bid was detected by immunofluorescence using Alexa Fluor 488 conjugated mouse anti-HA IgG (Invitrogen). Microscopy was performed using a Zeiss (Thornwood, NY, USA) LSM 510 inverted confocal microscope.

**IP.** For endogenous IP, the chromatin-enriched nuclear fractions of Bid<sup>+/+</sup> MPCs or U2OS cells were collected and lysed in lysis buffer (25 mM HEPES pH 7.5, 250 mM NaCl, 2 mM EDTA, 10% glycerol, 0.5% NP-40, 1 mM PMSF, 4 μg/ml leupeptin/antipain, 0.1 mM orthovanadate, 1 mM NaF). Then, biotinylated anti-human/mouse Bid goat polyclonal antibody (R&D Systems, Minneapolis, MN, USA, BAF860), anti-Atrip 403,<sup>9</sup> anti-RPA70 (US biological, R3400), control IgG (Santa Cruz, Santa Cruz, CA, USA), was added to the lysate, and incubated at 4 °C for 1 h as indicated in the figure legends. Streptavidin agarose (Novagen, Gibbstown, NJ, USA), TrueBlot anti-Rabbit Ig IP Beads (cat no. 00-8800, eBioscience Inc., San Diego, CA, USA) or TrueBlot anti-mouse Ig IP Beads (cat no. 00-8811, eBioscience Inc.) were added and samples were incubated at 4 °C for 2 h. The beads were pelleted, washed, boiled with 5 × Laemmli buffer and the supernatant was resolved on SDS-PAGE. For domain mapping experiments, the indicated Bid constructs in pcDNA3 vectors and the indicated HA-tagged Atrip constructs in pLPCX vector (from Dr. David Cortez) were transfected using Lipofectamine (Invitrogen) and expressed in 293T cells for 48 h. Total cell lysates were prepared and IP was performed as indicated in the figure legend.

**Protein purification and *in vitro* interaction.** The *E. coli* BL21 strains harboring Atrip/pSV282 (a generous gift from Dr. David Cortez) were induced by 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at room temperature for 8 h and the His-MBP-Atrip fusion protein was purified as previous described,<sup>40</sup> wide-type or mutated mouse Bid cDNA was cloned into pGEX-6P-1 vectors and induced in BL21 strains by 1 mM IPTG at 37 °C for 4 h. The harvested cells were resuspended in lysis buffer (50 mM Tris-HCl, 50 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM DTT, 1 mM PMSF, pH 8.0) and centrifuged at 20 000 g for 20 min at 4 °C. After incubation with glutathione-agarose for 3 h at 4 °C the supernatant was discarded and the beads were incubated with prescission protease (GE Healthcare Bioscience, Piscataway, NJ, USA) at 4 °C overnight. The Bid protein in the supernatant was dialyzed in 30 mM Tris-HCl (pH 8.0).

For the Bid-Atrip *in vitro* interaction, 10 μg Bid and 100 μg His-MBP-Atrip protein were incubated in binding buffer (20 mM HEPES, 100 mM KCl, 5 mM MgCl<sub>2</sub>, 0.5 mM EDTA, 0.1% NP-40, pH7.5) at room temperature for 30 min. Then biotinylated anti-human/mouse Bid goat polyclonal antibody (R&D Systems, BAF860) was added and incubated at 4 °C for 1 h. Streptavidin agarose (Novagen) was then added and incubated at 4 °C for 2 h. The beads were pelleted by centrifugation and washed four times with binding buffer. The beads were boiled with 5 × Laemmli buffer and the supernatant was subjected to SDS-PAGE.

**Chk1 IP-kinase assay.** U2OS cells transfected with control siRNA or Bid siRNA (no. 8) for 72 h were treated with 10 mM HU for 2 h. The cells were lysed in IP buffer (25 mM HEPES, 250 mM NaCl, 2 mM EDTA, 0.5 NP-40, 10 % glycerol, 4 μg/ml leupeptin/antipain, 1 mM PMSF, 10 mM β-glycerophosphate, 0.1 mM orthovanadate, 1 mM NaF, pH 7.5) and Chk1 was immunoprecipitated using polyclonal anti-Chk1 antibody (Chemicon, Temecula, CA, USA, AB3539) and protein G sepharose (Invitrogen). The immunoprecipitated products were washed once with kinase buffer (10 mM HEPES, 50 mM NaCl, 50 mM β-glycerophosphate, 10 mM MgCl<sub>2</sub>, 10 MnCl<sub>2</sub>, 1 mM DTT, pH 7.5) and incubated with 1 μg GST-Cdc25C protein (a generous gift from Dr. Jennifer Pietsenpol) on ice for 5 min. Then, 10 μM cold ATP and 5 μCi were added to the reaction. The kinase reactions were

performed at room temperature for 1 h and stopped by adding 5 × Laemmli buffer. Kinase reactions were resolved on SDS-PAGE. Gels were stained with SimplyBlue SafeStain (Invitrogen) according to the manufacturer's instructions, photographed, and dried before the autoradiography.

**Subcellular fractionation.** Subcellular fractionation of MPCs or U2OS cells were performed as previously described<sup>41</sup> with minor modification. In brief, 10 × 10<sup>6</sup> MPCs were washed once with PBS and suspended in 400 μl solution A (10 mM HEPES pH7.9, 10 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.34 M sucrose, 10% glycerol, 1 mM DTT, 1 mM PMSF, 10 mM NaF, 10 mM β-glycerophosphate, 1 μM microcystin) with 0.1% NP-40 on ice for 5 min. The cytoplasmic and nuclear fractions were collected by centrifugation at 1300 × g for 4 min at 4 °C. The isolated nuclei were washed once with solution A and then lysed in solution B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 1 mM PMSF, 10 mM NaF, 10 mM β-glycerophosphate, 1 μM microcystin). After incubation on ice for 10 min, chromatin fractions were harvested by centrifugation at 1700 × g for 4 min at 4 °C. The chromatin pellet was washed once with solution B and resuspended in 100 μl RIPA buffer. After sonication for 20 s, the samples were boiled with 5 × Laemmli buffer.

**Single-cell gel electrophoresis (Comet) assay.** U2OS cells overexpressing HA-tagged wild-type or helix 4-mutated hBid was transfected with Bid siRNA for 72 h. Silent mutations were introduced in the Bid siRNA-target region so that only endogenous Bid was knocked down by Bid siRNA. Then, cells were treated with HU overnight. The untreated and treated cells were collected in ice-cold PBS and alkaline Comet assay was performed by CometAssay Kit (Trevigen, Gaithersburg, MD, USA). Briefly, cells were mixed with molten LMAgarose and pipetted onto CometSlide. After incubation with Lysis Solution and Alkaline Solution, slides were placed in Genemate Compact Gel tank (Bioexpress, Kaysville, UT, USA) and TBE electrophoresis was performed at 22 V for 10 min. After incubation with 70% ethanol for 5 min, the slides were stained with SYBR green I. Then, samples were examined using a Leica DM IRBE inverted wide-field microscope and analyzed by CometScore Program Version 1.5.

**Antibodies.** The following antibodies were used in this study: anti-Bid rabbit polyclonal antibody,<sup>42</sup> anti-Bid polyclonal antibody (R&D Systems, BAF860), anti-Bid polyclonal antibody (Santa Cruz, FL-195), anti-Chk1 monoclonal antibody (Santa Cruz, G-4), anti-phospho-Chk1 (S345) polyclonal antibody (Cell signaling, 2341), anti-phospho-Chk1 (S317) polyclonal antibody (Cell signaling, 2344), anti-Cdc25A monoclonal antibody (Santa Cruz, F6), anti-Bax polyclonal antibody,<sup>43</sup> anti-Actin monoclonal antibody (Sigma), anti-histone H3 monoclonal antibody (Upstate Biotechnology, Waltham, MA, USA, 05-928), anti-IκB polyclonal antibody (Cell signaling, 9242), anti-p53 monoclonal antibody (Santa Cruz, Pab240), anti-phospho-p53(S15) polyclonal antibody (Cell signaling, 9284), anti-HA monoclonal antibody (Roche, 12CA5), and anti-Atrip polyclonal antibody (403; Cortez *et al.*<sup>9</sup>), anti-Atr polyclonal antibody (Santa Cruz, N-19), anti-RPA32 monoclonal antibody (Cell signaling, 2208), anti-RPA70 monoclonal antibody (US biological, R3400), anti-Mcl-1 polyclonal antibody (Rockland, Gilbertsville, PA, USA), anti-Bcl-2 monoclonal antibody (Pharmingen, San Diego, CA, USA), anti-RUNX1 antibody was a generous gift from Professor Hiebert.

### Conflicts of Interest

The authors declare no conflict of interest.

**Acknowledgements.** We thank Dr. Jennifer Pietsenpol, Dr. Scott Hiebert, Dr. David Cortez, Dr. Christine Eischen, Dr. Elizabeth Yang, Dr. Ellen Fanning, and Dr. Mark Boothby for many helpful discussions. We thank Dr. David Cortez for anti-Atrip antibody and Atr/Atrip cDNA. This work was supported by funds from the Sidney Kimmel Foundation, the G&P Foundation, ACS IRG-58-009-47, NIH K08 CA098394, and R01 HL088347 to SSZ. Cell imaging experiments were performed in the VUMC Cell Imaging Shared Resource.

1. Kamer I, Sarig R, Zaltsman Y, Niv H, Oberkovitz G, Regev L *et al*. Proapoptotic BID is an ATM effector in the DNA-damage response. *Cell* 2005; **122**: 593–603.
2. Zinkel SS, Hurov KE, Ong C, Abtahi FM, Gross A, Korsmeyer SJ. A role for proapoptotic BID in the DNA-damage response. *Cell* 2005; **122**: 579–591.

3. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B *et al*. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. *Nature* 1999; **400**: 886–891.
4. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. *Cell* 1998; **94**: 491–501.
5. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. *Cell* 1998; **94**: 481–490.
6. Zinkel SS, Ong CC, Ferguson DO, Iwasaki H, Akashi K, Bronson RT *et al*. Proapoptotic BID is required for myeloid homeostasis and tumor suppression. *Genes Dev* 2003; **17**: 229–239.
7. Matsuoka S, Ballif BA, Smogorzewska A, McDonald III ER, Hurov KE, Luo J *et al*. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. *Science* 2007; **316**: 1160–1166.
8. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. *Annu Rev Biochem* 2004; **73**: 39–85.
9. Cortez D, Guntuku S, Qin J, Elledge SJ. ATR and ATRIP: partners in checkpoint signaling. *Science* 2001; **294**: 1713–1716.
10. Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. *Nature* 2005; **434**: 605–611.
11. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. *Science* 2003; **300**: 1542–1548.
12. Ball HL, Ehrhardt MR, Mordes DA, Glick GG, Chazin WJ, Cortez D. Function of a conserved checkpoint recruitment domain in ATRIP proteins. *Mol Cell Biol* 2007; **27**: 3367–3377.
13. Bermudez VP, Lindsey-Boltz LA, Cesare AJ, Maniwa Y, Griffith JD, Hurwitz J *et al*. Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex *in vitro*. *Proc Natl Acad Sci USA* 2003; **100**: 1633–1638.
14. Zou L, Cortez D, Elledge SJ. Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin. *Genes Dev* 2002; **16**: 198–208.
15. Delacroix S, Wagner JM, Kobayashi M, Yamamoto K, Karnitz LM. The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1. *Genes Dev* 2007; **21**: 1472–1477.
16. Mordes DA, Glick GG, Zhao R, Cortez D. TopBP1 activates ATR through ATRIP and a PIKK regulatory domain. *Genes Dev* 2008; **22**: 1478–1489.
17. Wang J, Iwasaki H, Krivtsov A, Febbo PG, Thorner AR, Ernst P *et al*. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. *EMBO J* 2005; **24**: 368–381.
18. Stracker TH, Morales M, Couto SS, Hussein H, Petriani JH. The carboxy terminus of NBS1 is required for induction of apoptosis by the MRE11 complex. *Nature* 2007; **447**: 218–221.
19. Kaufmann T, Tai L, Ekert PG, Huang DC, Norris F, Lindemann RK *et al*. The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. *Cell* 2007; **129**: 423–433.
20. Myers K, Gagou ME, Zuazua-Villar P, Rodríguez R, Meuth M. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress. *PLoS Genet* 2009; **5**: e1000324.
21. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS. BID regulation by p53 contributes to chemosensitivity. *Nat Cell Biol* 2002; **4**: 842–849.
22. Casper AM, Nghiem P, Art MF, Glover TW. ATR regulates fragile site stability. *Cell* 2002; **111**: 779–789.
23. Shimuta K, Nakajo N, Uto K, Hayano Y, Okazaki K, Sagata N. Chk1 is activated transiently and targets Cdc25A for degradation at the *Xenopus* midblastula transition. *EMBO J* 2002; **21**: 3694–3703.
24. Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S *et al*. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. *J Biol Chem* 2003; **278**: 21767–21773.
25. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. *Curr Opin Genet Dev* 2001; **11**: 71–77.
26. Fisher D, Mechali M. Sleeping policemen for DNA replication? *Nat Cell Biol* 2004; **6**: 576–577.
27. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. *Nature* 2004; **432**: 316–323.
28. Maya-Mendoza A, Petermann E, Gillespie DA, Caldecott KW, Jackson DA. Chk1 regulates the density of active replication origins during the vertebrate S phase. *EMBO J* 2007; **26**: 2719–2731.
29. Chou JJ, Li H, Salvesen GS, Yuan J, Wagner G. Solution structure of BID, an intracellular amplifier of apoptotic signaling. *Cell* 1999; **96**: 615–624.
30. McDonnell JM, Fushman D, Millman CL, Korsmeyer SJ, Cowburn D. Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists. *Cell* 1999; **96**: 625–634.
31. Ball HL, Cortez D. ATRIP oligomerization is required for ATR-dependent checkpoint signaling. *J Biol Chem* 2005; **280**: 31390–31396.
32. Cheng WC, Berman SB, Ivanovska I, Jonas EA, Lee SJ, Chen Y *et al*. Mitochondrial factors with dual roles in death and survival. *Oncogene* 2006; **25**: 4697–4705.
33. Danial NN, Walensky LD, Zhang CY, Choi CS, Fisher JK, Molina AJ *et al*. Dual role of proapoptotic BAD in insulin secretion and beta cell survival. *Nat Med* 2008; **14**: 144–153.
34. Burrows AE, Elledge SJ. How ATR turns on: TopBP1 goes on ATRIP with ATR. *Genes Dev* 2008; **22**: 1416–1421.
35. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. *Nat Rev* 2008; **9**: 616–627.
36. Jamil S, Mojtavavi S, Hojabrpour P, Cheah S, Duronio V. An essential role for MCL-1 in ATR-mediated CHK1 phosphorylation. *Mol Biol Cell* 2008; **19**: 3212–3220.
37. Jamil S, Stoica C, Hackett TL, Duronio V. MCL-1 localizes to sites of DNA damage and regulates DNA damage response. *Cell Cycle* 2010; **9**: 2843–2855.
38. Zinkel SS, Hurov KE, Gross A. Bid plays a role in the DNA damage response. *Cell* 2007; **130**: 9–10 author reply 10–11.
39. Olsson M, Vakifahmetoglu H, Abruzzo PM, Hogstrand K, Grandien A, Zhivotovskiy B. DISC-mediated activation of caspase-2 in DNA damage-induced apoptosis. *Oncogene* 2009; **28**: 1949–1959.
40. Liu Y, Zhao TJ, Yan YB, Zhou HM. Increase of soluble expression in *Escherichia coli* cytoplasm by a protein disulfide isomerase gene fusion system. *Protein Expr Purif* 2005; **44**: 155–161.
41. Méndez J, Stillman B. Chromatin association of human origin recognition complex, cdc6, and minichromosome maintenance proteins during the cell cycle: assembly of prereplication complexes in late mitosis. *Mol Cell Biol* 2000; **20**: 8602–8612.
42. Wang K, Yin XM, Chao DT, Millman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. *Genes Dev* 1996; **10**: 2859–2869.
43. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. *Proc Natl Acad Sci USA* 1996; **93**: 14559–14563.

Supplementary Information accompanies the paper on Cell Death and Differentiation website (<http://www.nature.com/cdd>)